Loading organizations...
§ Private Profile · 25 North Wall Quay, Dublin 1, D1 H104
Biopharmaceutical company developing differentiated anti-infectives for multi-drug resistant pathogens, with ORLYNVAH for uUTIs.
Iterum Therapeutics is a biopharmaceutical company based in Dublin, Ireland, focused on developing differentiated anti-infectives to combat multi-drug resistant pathogens and improve lives affected by serious infections. The publicly traded company (Nasdaq: ITRM) operates with a lean team of 9 employees. Its lead product, ORLYNVAH (sulopenem), received FDA approval in October 2024, marking it as the first and only oral penem for uncomplicated urinary tract infections in patients with limited oral antibiotic options. CEO Corey Fishman, a pharmaceutical veteran with over 30 years of experience, has a notable history of leading over $600 million in capital raises and two $1.5 billion company sales. Former chief scientific officer Michael Dunne, MD, is another key figure associated with the firm. Iterum Therapeutics was founded in 2015 by former executives of Durata Therapeutics.
Iterum Therapeutics has raised $105.0M across 2 funding rounds.
Iterum Therapeutics has raised $105.0M in total across 2 funding rounds.
Iterum Therapeutics has raised $105.0M across 2 funding rounds. Most recently, it raised $65.0M Series B in May 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2017 | $65M Series B | Arix Bioscience | Canaan Partners, RED Tree Venture Capital, Shahzad Malik, BAY City Capital, Canaan Partners, Domain Associates, Frazier Healthcare Partners, NEW Leaf Venture Partners, Tracy Saxton, Sofinnova Investments | Announced |
| Mar 1, 2016 | $40M Series A | Patrick Heron | Canaan Partners, RED Tree Venture Capital, Brent Ahrens, RON Hunt, James Healy | Announced |
Iterum Therapeutics has raised $105.0M in total across 2 funding rounds.
Iterum Therapeutics's investors include Arix Bioscience, Canaan Partners, Red Tree Venture Capital, Shahzad Malik, Bay City Capital, Domain Associates, Frazier Healthcare Partners, New Leaf Venture Partners, Tracy Saxton, Sofinnova Ventures, Patrick Heron, Brent Ahrens.
Iterum Therapeutics plc (ITRM) is a clinical-stage pharmaceutical company developing differentiated anti-infectives to combat multi-drug resistant pathogens. It focuses on sulopenem, a novel penem antibiotic available in oral (ORLYNVAH™) and IV formulations, targeting serious infections like uncomplicated urinary tract infections (uUTIs) caused by resistant bacteria such as *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* in adult women with limited treatment options[1][2]. The company serves physicians, patients, and healthcare systems by addressing the global crisis of antibiotic resistance, where over two million Americans face resistant infections annually, leading to at least 23,000 deaths[4]. ORLYNVAH™ received U.S. FDA approval, marking a key commercialization milestone, while sulopenem shows potent in vitro activity against gram-negative, gram-positive, and anaerobic bacteria[1][3].
Iterum was founded in 2015 with the goal of tackling multi-drug resistant pathogens, particularly for common conditions like uUTIs and intra-abdominal infections (IAIs)[3]. The idea emerged from licensing sulopenem—a promising experimental penem antibiotic originally developed by Pfizer but shelved when Pfizer shifted therapeutic focus[3]. Iterum rescued the compound, overcame manufacturing challenges to create oral and IV forms, and advanced it through development, including Phase 3 programs and FDA approval for ORLYNVAH™[1][3]. Early traction came from recognizing sulopenem's potential against resistant gram-negative infections in both hospital and community settings, responding to clinician demands for effective, non-hospital therapies to reduce costs and infection risks[3].
Iterum rides the critical trend of antimicrobial resistance (AMR), a global crisis driving demand for new antibiotics amid rising multi-drug resistant infections[1][4]. Timing is pivotal as pathogens evolve resistance to current treatments, with clinicians needing community-administrable options to curb hospital stays and costs—sulopenem directly addresses this for high-burden conditions like uUTIs[3]. Market forces favoring Iterum include regulatory support (e.g., FDA approval) and stakeholder urgency for therapies against gram-negative superbugs, influencing the ecosystem by reviving stalled innovations and enabling oral alternatives to IV-only drugs[1][3]. As a single-segment player in anti-infectives, it contributes to pharma's push against AMR, potentially reducing mortality from over two million U.S. cases yearly[4][5].
Iterum's FDA-approved ORLYNVAH™ positions it for commercialization growth, with ongoing sulopenem advancements (e.g., IV formulation, expansions beyond uUTIs) likely driving revenue amid AMR escalation[1][2]. Trends like increasing resistance, post-pandemic infection awareness, and incentives for novel antibiotics will shape its path, potentially expanding to IAIs or global markets[3][4]. Influence may evolve through partnerships or acquisitions, amplifying its role in outpatient anti-infective solutions—ultimately delivering on its promise to improve lives against resistant pathogens[1][3].